Subsequently, the target genes from the PharmMapper database, DEGs from the GSE73500 and GSE89632 datasets, and NAFLD-related genes from the GeneCards database were subjected to Venn analysis, with seven target genes of dehydrovomifoliol in NAFLD treatment obtained (Figure 2(e)), namely E2F1, MERTK, SOX17, MMP9, SULT2A1, VEGFA, and BLVRA. Here, SOX17 is linked to metabolic dysfunction-associated steatotic liver disease.